leading brands of glp-1 agonists in biopharma The Landscape Receptor Diabetes And Obesity Treatment GLP-1 Receptor Agonist Shortage: Challenges
Description
According to primary trials in T2DM, tirzepatide significantly reduces clinical outcomes like body weight, glycated hemoglobin (HbA1c), lipid profiles, and glucose-adjusted glucagon secretion compared to typical glucagon-like peptide1 receptor agonists (GLP1RAs) [1, 2]

2023;63(4S):s25-s30

Ortega FB, Lavie CJ, Blair SN

Glucagon-like peptide-1 attenuates endothelial barrier injury in diabetes via cAMP/PKA mediated down-regulation of MLC phosphorylation

These side effects may affect treatment adherence and long-term persistence